Literature DB >> 24664980

Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance.

Udho Thadani1.   

Abstract

Nitrate therapy has been an effective treatment for ischemic heart disease for over 100 years. The anti-ischemic and exercise-promoting benefits of sublingually administered nitrates are well established. Nitroglycerin is indicated for the relief of an established attack of angina and for prophylactic use, but its effects are short lived. In an effort to increase the duration of beneficial effects, long-acting orally administered and topical applications of nitrates have been developed; however, following their continued or frequent daily use, patients soon develop tolerance to these long-acting nitrate preparations. Once tolerance develops, patients begin losing the protective effects of the long-acting nitrate therapy. By providing a nitrate-free interval, or declining nitrate levels at night, one can overcome or reduce the development of tolerance, but cannot provide 24-h anti-anginal and anti-ischemic protection. In addition, patients may be vulnerable to occurrence of rebound angina and myocardial ischemia during periods of absent nitrate levels at night and early hours of the morning, and worsening of exercise capacity prior to the morning dose of the medication. This has been a concern with nitroglycerin patches but not with oral formulations of isosorbide-5 mononitrates, and has not been adequately studied with isosorbide dinitrate. This paper describes problems associated with nitrate tolerance, reviews mechanisms by which nitrate tolerance and loss of efficacy develop, and presents strategies to avoid nitrate tolerance and maintain efficacy when using long-acting nitrate formulations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24664980     DOI: 10.1007/s40256-014-0072-5

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  7 in total

Review 1.  Relief of Ischemia in Ischemic Cardiomyopathy.

Authors:  Francesco Moroni; Zachary Gertz; Lorenzo Azzalini
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 2.  The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics.

Authors:  Sanjay Divakaran; Joseph Loscalzo
Journal:  J Am Coll Cardiol       Date:  2017-11-07       Impact factor: 24.094

Review 3.  Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris.

Authors:  Jason M Tarkin; Juan Carlos Kaski
Journal:  Eur Cardiol       Date:  2018-08

Review 4.  Drug Therapy for Stable Angina Pectoris.

Authors:  Talla A Rousan; Sunil T Mathew; Udho Thadani
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

5.  Switching from nitrate therapy to ranolazine in patients with coronary artery disease receiving phosphodiesterase type-5 inhibitors for erectile dysfunction.

Authors:  Dioma U Udeoji; Ernst R Schwarz
Journal:  Clin Med Insights Case Rep       Date:  2014-11-19

6.  Nitrates vs. Other Types of Vasodilators and Clinical Outcomes in Patients with Vasospastic Angina: A Propensity Score-Matched Analysis.

Authors:  Hyun-Jin Kim; Sang-Ho Jo; Min-Ho Lee; Won-Woo Seo; Hack-Lyoung Kim; Kwan Yong Lee; Tae-Hyun Yang; Sung-Ho Her; Byoung-Kwon Lee; Keun-Ho Park; Youngkeun Ahn; Seung-Woon Rha; Hyeon-Cheol Gwon; Dong-Ju Choi; Sang Hong Baek
Journal:  J Clin Med       Date:  2022-06-07       Impact factor: 4.964

Review 7.  Vasodilator Therapy: Nitrates and Nicorandil.

Authors:  Jason M Tarkin; Juan Carlos Kaski
Journal:  Cardiovasc Drugs Ther       Date:  2016-08       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.